The AI-designed pan-H5Nx vaccine candidate begins human clinical trials by November 2028.
Following successful animal challenge tests in mice and ferrets, researchers aim to advance the computational vaccine into human trials.
Across 6 frontier models answering independently, the panel leans no: the median is 40%.
They do not agree: Gemini puts it at 68% and Claude at 27%, 41 points apart. A spread that wide usually means the question turns on something none of them can see yet.
Nothing is settled until 15 Nov 2029, when the outcome is checked against sources and every number above gets a permanent score.
What each one said
-
GeminiGoogle
Advancing from positive ferret data to Phase 1 trials takes roughly 18-24 months if funding and IND clearance hold.
- A 24-month window gives ample time to complete GLP toxicology, GMP manufacturing, and FDA IND filing before November 2028.
- Pan-influenza vaccines face high attrition in scale-up, but ongoing H5N1 spillover urgency accelerates BARDA/CEPI backing.
- Failure would likely stem from unexpected reactogenicity in pre-IND non-human primate studies or formulation instability.
68% -
GPTOpenAI
The key determinant is whether animal efficacy translates into a fundable GMP, toxicology, and IND package on schedule.
- A sponsor, manufacturer, and regulator must complete process development, GLP tox, and an FDA IND/other trial authorization before 15 November 2029.
- First-in-human vaccine programs commonly need roughly 2–4 years after strong ferret data; three years is feasible but leaves little room for reformulation.
- Confidence rises sharply with disclosed GMP manufacturing and an IND-enabling study in 2027; weak durability or safety findings would likely push it past 2029.
63% -
DeepSeekDeepSeek
Whether a computational pan-H5Nx vaccine clears IND-enabling tox and GMP manufacturing in time to dose a first volunteer by late 2028.
- The team must file an IND with FDA and get a 'may proceed' letter; typical first-in-human vaccines take 18-30 months from lead candidate to dosing.
- Precedent: mRNA pandemic candidates in 2020 went from sequence to Phase 1 in ~65 days, but that was Operation Warp Speed funding with pre-existing platforms.
- A universal flu vaccine has never reached licensure; H5Nx candidates like the NIH's H5N1 mRNA entered Phase 1 in 2023, showing the path exists but is slow.
42% -
GrokxAI
GMP manufacture plus IND/ethics clearance in ~24 months after ferret data.
- Sponsors must lock a process, make clinical lots, and file IND/CTA by mid-2028; novel computational antigens add extra CMC and immunogenicity questions.
- Historic flu/pandemic candidates that clear rodents/ferrets enter Phase 1 in 12–36 months when funded; two-year window sits at the slower end of that distribution.
- A BARDA/CEPI or pharma partnership announced in 2027 would raise odds sharply; otherwise manufacturing or regulatory hold is the modal delay.
38% -
QwenAlibaba
GMP manufacturing and IND clearance are the binding constraints; H5N1 cattle urgency helps but 2 years is tight.
- From completed animal challenge data, GMP production plus IND filing plus site activation typically takes 18–30 months; the 24-month window leaves little slack for…
- BARDA and NIH have accelerated H5 vaccine funding since the 2024 dairy cattle outbreak, which could compress regulatory timelines, but AI-designed constructs lack deep…
- A single manufacturing lot failure or FDA clinical hold would push past the deadline; the most likely positive surprise would be an existing GMP facility already…
38% -
ClaudeAnthropic
Hinges on whether preclinical/CMC work and IND-equivalent filing finish fast enough post animal-trial success.
- Moving from successful ferret/mouse challenge studies to IND filing and Phase 1 dosing typically takes 2-4 years given CMC, toxicology, and regulatory review.
- Base rate for novel computational/AI-designed vaccines hitting human trials within ~3 years of promising animal data is moderate but not high, especially for complex…
- Pandemic-preparedness funding (BARDA, CEPI) could accelerate timelines if H5N1 spread intensifies, which would push this higher.
27%
6 of 6 models answered · 41 points between the highest and lowest. None was shown the market price.
Question sourced from a news sweep on 16 Nov 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.